NCT00517569View on ClinicalTrials.gov

Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
HIV Infections
Interventions
GENETIC

GX-12

a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)

DRUG

HAART

Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.

Trial Locations (1)

110-744

RECRUITING

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

Genexine, Inc.

INDUSTRY

NCT00517569 - Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter